Biogen Idec Ma Inc.

Other

Biogen Ma Inc.

Curis, Inc.

Biogen Idec, Inc.

Dingyi Wen

R Blake Pepinsky

Ellen A Garber

Yen-Ming Hsu

Christine Ambrose

Jeffrey Thompson

Yaping Sun

Paul H Weinreb

Alexey Alexandrovich Lugovskoy

Jeffrey A Porter

Frederick Robbins Taylor

Werner Meier

Kevin P Williams

Laura Silvian

Daniel H S Lee

Rashmi Rohit Kshirsagar

Jane K Relton

Darren P Baker

Xinzhong Wang

Alphonse Galdes

Karin Lucas

David Evans

Russell Colyn Petter

Kathryn Strauch

Chenhui Zeng

Daniel Hs Lee

Daniel HS Lee

The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.

Methods of preventing and removing trisulfide bonds

Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Nogo receptor antagonists and methods of increasing neurite outgrowth

The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.

Method of treating B cell cancers by administering truncated BAFF receptors

Nogo receptor antagonists

The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.

Method of treating immunological disorders by administering truncated BAFF receptors

Truncated BAFF receptors

Truncated baff receptors

Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.

Hydrophobically-modified protein compositions and methods

Hydrophobically-modified hedgehog protein compositions and methods

Growing community of inventors

Waltham, MA, United States of America

Dingyi Wen